A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer

BACKGROUND: Preclinical and early clinical data support the use of Vascular Epithelial Growth Factor (VEGF)-targeted therapy with trastuzumab in Human Epidermal Receptor 2 (HER2) positive breast cancer. Adding bevacizumab to a taxane (docetaxel or paclitaxel) improves progression free survival (PFS)...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Invest New Drugs
Asıl Yazarlar: Zhao, Meng, Pan, Xueliang, Layman, Rachel, Lustberg, Maryam B., Mrozek, Ewa, Macrae, Erin R., Wesolowski, Robert, Carothers, Sarah, Puhalla, Shannon, Shapiro, Charles L., Ramaswamy, Bhuvaneswari
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4303337/
https://ncbi.nlm.nih.gov/pubmed/24894652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0122-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller